Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reverse OLIGO study in oligo-progressive non-small cell lung cancer during first-line immunotherapy
jRCTs031220630Phase 2Recruiting
- Start
- Jul 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab, pemetrexed, atezolizumab, nivolumab, ipilimumab and 2 more in non-small cell lung cancer (NSCLC) (2 arms). Primary endpoint: Progression-free survival. Started Jul 2023; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs031220630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220630.